JESSICA VIGOA: Open Payments
NPI 1922471903 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,427 in 91 payments from 18 companies in 2025. Trend: 2023 $1,853 · 2024 $2,485 · 2025 $2,427
Food & beverage: $2,393Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $497 |
| GlaxoSmithKline, LLC. | 20 | $412 |
| Regeneron Healthcare Solutions, Inc. | 13 | $352 |
| GENZYME CORPORATION | 6 | $215 |
| BioCryst US Sales Co., LLC | 11 | $210 |
| Amgen Inc. | 7 | $140 |
| Genentech, Inc. | 1 | $139 |
| Novartis Pharmaceuticals Corporation | 4 | $100 |
| Genentech USA, Inc. | 3 | $65 |
| Lilly USA, LLC | 2 | $60 |
Products named: TEZSPIRE, DUPIXENT, NUCALA, ORLADEYO, Xolair, TRELEGY ELLIPTA, EBGLYSS, Andembry.
Industry payments across FL — which companies pay providers there.
